Name | HFI-419 |
---|
Description | HFI-419 is an insulin-regulated aminopeptidase (IRAP) inhibitor. HFI-419 has inhibitory potency for IRAP with Ki value of 0.48 μM. HFI-419 can be used for the research of cognitive and memory impairments such as Alzheimer's disease, brain trauma, and stroke[1]. |
---|---|
Related Catalog | |
Target |
Ki: 0.48 μM (IRAP)[1] |
In Vitro | HFI-419 inhibits IRAP with a Ki value of 0.48 μM[1]. HFI-419 (1 μM) shows rapid disappearance that is associated with nonenzymatic (such as amide hydrolysis) processes[1]. |
In Vivo | HFI-419 (i.v, i.p; 2, 10 mg/kg) exhibits brain exposure and also exhibits potent inhibition of IRAP[1]. Animal Model: Sprague-Dawley rats[1] Dosage: 2 mg/kg, 10 mg/kg Administration: Intravenous, intraperitoneal Result: Exhibited a short apparent elimination half-life, a high plasma clearance and a large volume of distribution. Extended the apparent half-life to 4.6 h. |
Molecular Formula | C19H18N2O5 |
---|---|
Molecular Weight | 354.36 |